This case is about an HIV seropositive young woman referred for the treatment of severe menorrhagia causing anaemia due to adenomyosis where the levonorgestrel-releasing intrauterine system (Mirena®) proved useful in treating her heavy periods and also provided effective contraception without interference from the liver enzyme-inducing effects of antiretroviral medications.
DeffieuxX, FernandezH.Physiopathologic, diagnostic and therapeutic evolution in the management of adenomyosis: review of the literature.J Gynecol Obstet Biol Reprod2004; 33: 703–12.
2.
ThomasJSJr, ClarkJF.Adenomyosis: a retrospective view.J Natl Med Assoc1989; 81: 969–72.
3.
BackmanT.Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.Drug Saf2004; 27: 1185–204.
4.
StewartA, CumminsC.The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review.BJOG2001; 108: 74–6.
5.
FFPRHC Guidance.Drug interactions with hormonal contraception.J Fam Plann Reprod Health Care2005; 31: 139–51.
6.
BoundsW, GuillebaudJ.Observational series on women using the contraceptive Mirena® concurrently with anti-epileptic and other enzyme inducing drugs.J Fam Plan Reprod Health Care2002; 2: 78–80.
